Encochleated amikacin - Matinas BioPharma

Drug Profile

Encochleated amikacin - Matinas BioPharma

Alternative Names: C-Amikacin; MAT 2501

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Mycobacterial infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 31 Dec 2016 Phase-I clinical trials in Mycobacterial infections in USA (PO) before December 2016
  • 22 Jun 2016 Matinas Biopharma has patent protection for Encochleated amikacin in USA
  • 20 Jun 2016 Pharmacokinetics and adverse events data from preclinical studies in Non-tuberculous mycobacterium infections presented at the American Society for Microbiology's (ASM's) General Meeting combined with its Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (ASMM-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top